Pila Pharma
powered by Stokk.io

H2 Presentation and Q&A

Thu, 27 Feb, 2025, 15:00 – 16:00
This event has ended. Sign up below to watch the recording.
Sign in to access all the features of the platform.

How does this Q&A work:

This company invites all interested, both current investors and potential investors to participate in this event, ask questions directly on this page before the event starts and upvote those questions you would like addressed.

The company will address as many questions as possible, and focus on those questions most wanted by investors.

Speakers at this event:

Gustav Hanghøj Gram
CEO
Hampus Darrell
CFO

11 Questions

A
A**** *****
Feb. 27, 2025

How do you judge your increased burn-rate compared to 2023?
How much of the cash from your directed issue has been deployed yet?

Upvote
1 upvote
Answered by   Gustav Hanghøj Gram - CEO at Pila Pharma
See answer
R
Rutger Smith
Feb. 27, 2025

My main worry is the body temperature raising properties of the drug candidate. Is there any new insights into this issue?
On another note what would be the mode of action for the abdominal aorta aneurysm protecting property?

Upvote
0 upvotes
Answered by   Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma
See answer
H
Henning Hallen
Feb. 27, 2025

Is there an estimated completion date for Phase 3? What is the status regarding a potential partner? When will new funding be needed again?

Upvote
0 upvotes
Answered by   Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma
See answer
A
A**** *****
Feb. 27, 2025

How are the macro situation with US/EU affecting you and your share price?

Upvote
0 upvotes
Answered by   Gustav Hanghøj Gram - CEO at Pila Pharma
See answer
A
A**** *****
Feb. 27, 2025

Is your investor base becoming more international ?

Upvote
0 upvotes
Answered by   Gustav Hanghøj Gram - CEO at Pila Pharma
See answer
S
S**** *****
Feb. 27, 2025

Does any other companies use TRPV1 for these diseases?

Upvote
0 upvotes
Answered by   Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma
See answer
N
Niels Raaschou
Feb. 27, 2025

Dear Pila Team - Please elaborate on how the on-going test is progressing

Upvote
0 upvotes
Answered by   Gustav Hanghøj Gram - CEO at Pila Pharma
See answer
S
S**** *****
Feb. 27, 2025

What are the plans for your aorta aneurism project / results?

Upvote
0 upvotes
Answered by   Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma
See answer
S
S**** *****
Feb. 27, 2025

You’ve previously been focused and have results on diabetes – what is the plan for obesity?
How does your proposed product differ from the obesity products on the market?

Upvote
0 upvotes
Answered by   Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma
See answer
A
A**** *****
Feb. 27, 2025

What are your partnership plans – are you already talking to companies?

Upvote
0 upvotes
Answered by   Gustav Hanghøj Gram - CEO at Pila Pharma
See answer
P
P.K. Agarwal
Feb. 25, 2025

I would like to know where you are with assessing the efficacy of XEN-D0501 for erythromelalgia?

Upvote
0 upvotes
Answered by   Gustav Hanghøj Gram - CEO at Pila Pharma , Gustav Hanghøj Gram - CEO at Pila Pharma
See answer